Restriction_NN of_IN lentivirus_NN in_IN monkeys_NNS Retroviruses_NNS are_VBP able_JJ to_TO cross_VB species_NN barriers_NNS and_CC have_VBP done_VBN so_IN many_JJ times_NNS throughout_IN evolution_NN ._SENT Perhaps_RB as_IN a_DT consequence_NN ,_, dominant_JJ mechanisms_NNS have_VBP arisen_VBN to_TO block_VB infection_NN by_IN murine_JJ retroviruses_NNS in_IN mice_NNS (_( restriction_NN factor_NN Fv1_NP )_) and_CC humans_NNS (_( restriction_NN factor_NN Ref1_NP )_) ,_, as_RB well_RB as_IN in_IN other_JJ mammals_NNS ._SENT Here_RB we_PP describe_VBP a_DT block_NN to_TO HIV_NP and_CC simian_JJ immunodeficiency_NN virus_NN in_IN monkeys_NNS ._SENT Like_IN previously_RB described_VBN restrictions_NNS the_DT block_NN is_VBZ saturable_JJ and_CC gives_VBZ rise_NN to_TO multiple-hit_JJ infection_NN kinetics_NNS ._SENT Furthermore_RB ,_, like_IN restriction_NN of_IN murine_JJ leukemia_NN virus_NN in_IN humans_NNS ,_, the_DT block_NN is_VBZ before_RB reverse_JJ transcription_NN ._SENT Intriguingly_RB ,_, African_JJ green_JJ monkey_NN cells_NNS are_VBP able_JJ to_TO block_VB both_DT HIV_NP and_CC simian_JJ immunodeficiency_NN virus_NN ,_, and_CC each_DT virus_NN is_VBZ able_JJ to_TO saturate_VB and_CC abrogate_VB the_DT restriction_NN of_IN the_DT other_JJ ,_, suggesting_VBG that_IN a_DT common_JJ factor_NN is_VBZ responsible_JJ ._SENT Recent_JJ phylogenetic_JJ analysis_NN of_IN retroviral_JJ sequences_NNS has_VBZ suggested_VBN that_IN interspecies_NNS retroviral_JJ infection_NN between_IN mammals_NNS may_MD have_VB been_VBN frequent_JJ during_IN their_PP$ evolution_NN ._SENT Certainly_RB HIV_NP types_NNS 1_CD and_CC 2_CD are_VBP derived_VBN from_IN simian_JJ immunodeficiency_NN virus_NN from_IN chimpanzees_NNS (_( SIVcpz_NP )_) and_CC sooty_JJ mangabees_NNS (_( SIVsm_NP )_) ,_, respectively_RB ._SENT Despite_IN these_DT viruses_NNS '_POS ability_NN to_TO cross_VB species_NNS ,_, several_JJ nonimmunological_JJ blocks_NNS to_TO replication_NN in_IN foreign_JJ hosts_NNS have_VBP been_VBN demonstrated_VBN ._SENT Such_PDT a_DT block_NN exists_VBZ for_IN HIV_NP type_NN 1_CD (_( HIV-1_NP )_) in_IN rhesus_NN macaques_NNS ,_, the_DT major_JJ HIV-1_JJ primate_NN experimental_JJ model_NN ._SENT Much_JJ work_NN from_IN several_JJ groups_NNS has_VBZ focused_VBN on_IN the_DT reasons_NNS for_IN the_DT block_NN in_IN macaques_NNS ._SENT Experiments_NNS in_IN macaque_NN PBL_NN and_CC simian_JJ MAGI_NP cells_NNS have_VBP shown_VBN that_IN the_DT block_NN is_VBZ generally_RB ,_, although_IN not_RB always_RB ,_, before_IN completion_NN of_IN reverse_JJ transcription_NN ._SENT However_RB ,_, the_DT block_NN is_VBZ not_RB due_JJ to_TO an_DT inability_NN of_IN HIV-1_NP env_NP to_TO direct_VB entry_NN into_IN macaque_NN cells_NNS as_RB shown_VBN by_IN the_DT efficient_JJ replication_NN of_IN SHIVs_NP ,_, chimeras_NNS of_IN HIV-1_NP and_CC simian_JJ immunodeficiency_NN virus_NN from_IN macaques_NNS (_( SIVmac_NP )_) encoding_VBG HIV-1_JJ envelope_NN ,_, tat_NN ,_, rev_NN ,_, and_CC vpu_NN proteins_NNS and_CC SIVmac_NP gag-pro-pol_NP ._SENT Attempts_NNS to_TO map_VB the_DT determinant_NN for_IN the_DT block_NN more_RBR closely_RB have_VB been_VBN hampered_VBN by_IN the_DT difficulty_NN of_IN making_VBG functional_JJ HIV-SIV_NP gag-pol_NP fusions_NNS ._SENT However_RB ,_, a_DT SHIV_NP has_VBZ been_VBN produced_VBN with_IN an_DT HIV-1_JJ capsid-p2_JJ domain_NN replacing_VBG the_DT equivalent_JJ SIVmac_NP sequence_NN ._SENT This_DT virus_NN was_VBD able_JJ to_TO replicate_VB in_IN human_JJ cells_NNS but_CC not_RB macaque_NN PBL_NN ,_, strongly_RB implying_VBG a_DT determinant_NN in_IN capsid_NN ._SENT The_DT virus_NN incorporated_JJ cyclophilin_NN and_CC was_VBD inhibited_VBN by_IN a_DT cyclosporin_NN analogue_NN ,_, further_RBR demonstrating_VBG the_DT functional_JJ capsid_NN phenotype_NN of_IN HIV-1_NP ._SENT Unfortunately_RB ,_, the_DT converse_JJ SHIV_NP ,_, an_DT HIV-1_NP with_IN an_DT SIVmac_NP capsid-p2_NN region_NN ,_, was_VBD noninfectious_JJ ,_, demonstrating_VBG the_DT difficulty_NN of_IN obtaining_VBG such_JJ chimeras_NNS ._SENT Further_JJR experiments_NNS on_IN HIV-1_JJ infection_NN of_IN macaque_NN have_VBP shown_VBN that_IN the_DT coreceptor_NN may_MD somehow_RB be_VB involved_VBN ._SENT Although_IN expression_NN of_IN human_JJ CD4_NP allows_VBZ entry_NN of_IN HIV-1_NP into_IN simian_JJ MAGI_NP cells_NNS ,_, the_DT infection_NN is_VBZ nonproductive_JJ with_IN a_DT block_NN before_IN or_CC after_IN reverse_JJ transcription_NN depending_VBG on_IN the_DT HIV-1_NP strain_NN used_VBD ._SENT Expression_NN of_IN human_JJ coreceptor_NN ,_, however_RB ,_, facilitates_VBZ their_PP$ infection_NN by_IN HIV-1_NP ,_, suggesting_VBG that_IN certain_JJ entry_NN pathways_NNS may_MD be_VB able_JJ to_TO bypass_VB postentry_NN restrictions_NNS ._SENT We_PP have_VBP recently_RB characterized_VBN a_DT block_NN to_TO murine_JJ leukemia_NN virus_NN in_IN a_DT range_NN of_IN mammals_NNS ,_, which_WDT seems_VBZ to_TO be_VB due_JJ to_TO expression_NN of_IN a_DT saturable_JJ factor_NN in_IN the_DT resistant_JJ cells_NNS ._SENT This_DT block_NN to_TO infection_NN resembles_VBZ Fv1-mediated_JJ restriction_NN in_IN mice_NNS in_IN its_PP$ saturable_JJ nature_NN and_CC its_PP$ target_NN specificity_NN ._SENT Characterization_NN of_IN these_DT restrictions_NNS allowed_VBD us_PP to_TO develop_VB an_DT assay_NN based_VBN on_IN abrogation_NN or_CC saturation_NN of_IN restriction_NN ,_, depending_VBG on_IN the_DT ability_NN of_IN a_DT sensitive_JJ virus_NN to_TO soak_VB up_RP and_CC overcome_VB the_DT restriction_NN factor_NN ._SENT Whereas_IN previous_JJ assays_NNS have_VBP been_VBN dependent_JJ on_IN measuring_VBG relative_JJ infection_NN by_IN a_DT pair_NN of_IN viruses_NNS ,_, one_PP restricted_VBD and_CC one_CD not_RB ,_, this_DT assay_NN uses_VBZ a_DT single_JJ restricting_VBG virus_NN ._SENT We_PP have_VBP used_VBN this_DT assay_NN to_TO examine_VB blocks_NNS to_TO HIV-1-_NP and_CC SIVmac251-derived_NP vectors_NNS in_IN monkey_NN cell_NN lines_NNS ._SENT Although_IN rhesus_NN and_CC owl_NN monkey_NN cells_NNS have_VBP been_VBN described_VBN as_IN being_VBG refractory_JJ to_TO HIV-1_JJ infection_NN ,_, it_PP has_VBZ been_VBN unclear_JJ whether_IN these_DT cells_NNS possess_VBP factors_NNS preventing_VBG HIV-1_JJ infection_NN or_CC whether_IN HIV-1_NP is_VBZ unable_JJ to_TO interact_VB with_IN cell_NN factors_NNS supporting_VBG virus_NN infection_NN ._SENT Here_RB we_PP demonstrate_VBP the_DT presence_NN of_IN a_DT saturable_JJ factor_NN that_WDT is_VBZ specifically_RB able_JJ to_TO block_VB infection_NN of_IN lentiviruses_NNS ._SENT Cell_NN Lines_NNS ._SENT |_SYM FRhK4_NP and_CC LLC-MK2_NP were_VBD obtained_VBN from_IN the_DT Centro_NP Substrati_NP Cellulari_NP ,_, Brescia_NP ,_, Italy_NP ;_: and_CC OMK_NP ,_, TE671_NP ,_, and_CC SIRC_NP cells_NNS were_VBD from_IN the_DT European_JJ Collection_NN of_IN Cell_NP Cultures_NP ,_, Porton_NP Down_NP ,_, U.K._NP CV1_NP cells_NNS were_VBD a_DT kind_NN gift_NN of_IN P._NP Jat_NP ,_, Ludwig_NP Institute_NP for_IN Cancer_NP Research_NP ,_, London_NP ._SENT Cells_NNS were_VBD maintained_VBN as_IN recommended_VBN by_IN suppliers_NNS ._SENT Viral_JJ Vector_NP Preparation_NP ._SENT |_SYM Viral_NP vectors_NNS were_VBD prepared_VBN by_IN transfection_NN of_IN 293T_JJ cells_NNS by_IN using_VBG Fugene-6_NP (_( Roche_NP Molecular_NP Biochemicals_NP )_) as_RB follows_VBZ ._SENT To_TO make_VB HIV-1_JJ vectors_NNS ,_, confluent_JJ 293T_JJ cells_NNS were_VBD transfected_VBN on_IN a_DT 10-cm_NP plate_NN with_IN a_DT mixture_NN of_IN 18_CD mul_NN of_IN Fugene-6_NP in_IN 200_CD mul_NN of_IN OptiMEM_NP (_( GIBCOBRL_NP )_) with_IN 1_CD mug_NN of_IN pMDG_NP [_SYM vesicular_JJ stomatitis_NN virus_NN envelope_NN protein_NN (_( VSV-G_NP )_) expression_NN vector_NN ]_SYM ,_, 1_CD mug_NN of_IN p8.91_JJ HIV-1_NP gag-pol_NP expression_NN vector_NN ,_, and_CC 1.5_CD mug_NN of_IN retroviral_JJ expression_NN vector_NN encoding_VBG enhanced_JJ green_JJ fluorescent_JJ protein_NN (_( eGFP_NN )_) ,_, SIN_NP CSGW_NP ,_, a_DT kind_NN gift_NN of_IN A._NP Thrasher_NP ,_, Institute_NP of_IN Child_NP Health_NP ,_, University_NP College_NP London_NP ,_, U.K._NP or_CC SIN_NP CSPW_NP encoding_VBG puro_NN (_( puromycin_NN resistance_NN )_) ._SENT To_TO make_VB SIVmac_NP vectors_VBZ 1_CD mug_NN of_IN SIV3+_NP (_( SIVmac_NP gag-pol_NP expression_NN vector_NN )_) and_CC 1.5_CD mug_NN of_IN SIV-eGFP_NP or_CC SIV-beta-galactosidase_NP (_( LacZ_NP )_) (_( SIV_NP vectors_VBZ encoding_VBG eGFP_NN and_CC LacZ_NP ,_, respectively_RB )_) were_VBD used_VBN ._SENT SIVmac_NP plasmids_NNS were_VBD a_DT kind_NN gift_NN of_IN Francois-Loic_NP Cosset_NP ,_, Ecole_NP Normale_NP Superieure_NP de_NP Lyon_NP ,_, France_NP ._SENT Murine_JJ leukemia_NN virus_NN (_( MLV_NP )_) vectors_NNS were_VBD made_VBN by_IN using_VBG plasmids_NNS as_RB described_VBN ._SENT VSV-G_NP expression_NN vector_NN pMDG_NN was_VBD used_VBN to_TO supply_VB envelope_NN for_IN most_JJS SIV_NP and_CC MLV_NP preparations_NNS ,_, whereas_IN a_DT cytomegalovirus_NN promoter-driven_JJ expression_NN plasmid_NN ,_, a_DT gift_NN of_IN F.-L_NP ._SENT Cosset_NN ,_, was_VBD used_VBN to_TO produce_VB an_DT HIV-eGFP_NP vector_NN bearing_NN amphotropic_JJ MLV_NP Env_NP ._SENT Viral_JJ supernatant_JJ was_VBD collected_VBN at_IN 48_CD ,_, 72_CD ,_, and_CC 96_CD h_NN after_IN transfection_NN and_CC stored_VBD at_IN -80C_NN ._SENT When_WRB required_VBN ,_, virus_NN was_VBD concentrated_VBN by_IN centrifugation_NN at_IN 17,000_CD rpm_NN in_IN an_DT SW28_NP rotor_NN for_IN 2_CD h._NNS The_DT pellet_NN was_VBD resuspended_VBN in_IN 1_CD /10_CD volume_NN media_NNS ._SENT Viral_JJ Titer_NP Determination_NP ._SENT |_SYM All_NP HIV-1_NP and_CC SIVmac_NP vector_NN titers_NNS were_VBD measured_VBN on_IN the_DT permissive_JJ human_JJ cell_NN line_NN TE671_NP ,_, and_CC titers_NNS are_VBP described_VBN as_IN TE671_JJ infectious_JJ units_NNS (_( i.u._NP )_) /ml_NN ._SENT HIV-eGFP_NP titers_NNS were_VBD determined_VBN 48_CD h_NN after_IN infection_NN by_IN a_DT fluorescence-activated_JJ cell_NN sorter_NN (_( FACS_NP )_) as_RB described_VBD ._SENT HIV-puro_NP titer_NN was_VBD measured_VBN by_IN infection_NN of_IN TE671_JJ cells_NNS and_CC colony_NN counting_NN after_IN selection_NN in_IN 1_CD mug_NN /ml_NN puromycin_NN ._SENT SIV-LacZ_NP titers_NNS were_VBD determined_VBN 48_CD h_NN after_IN infection_NN and_CC LacZ_NP staining_VBG as_RB described_VBN ._SENT Abrogation_NN Assays_NNS ._SENT |_SYM Abrogation_NP assays_NNS were_VBD performed_VBN in_IN six-well_NN plates_NNS on_IN 105_CD cells_NNS in_IN 1_CD ml_NN containing_VBG 5_CD mug_NN /ml_NN Polybrene_NP ._SENT Cells_NNS were_VBD exposed_VBN to_TO HIV-puro_NP or_CC SIV-LacZ_NP for_IN 4_CD h._NP Cells_NP were_VBD washed_VBN and_CC exposed_VBN to_TO HIV-eGFP_NP or_CC SIV-eGFP_NP ._SENT eGFP_NN fluorescence_NN was_VBD measured_VBN 48_CD h_NN later_RBR by_IN FACS_NP analysis_NN on_IN a_DT Becton_NP Dickinson_NP FACScan_NP or_CC LSR_NP by_IN using_VBG CELLQUEST_NP software_NN as_RB described_VBD ._SENT In_IN titration_NN experiments_NNS in_IN Figs._NP and_CC ,_, 50,000_CD cells_NNS were_VBD analyzed_VBN by_IN FACS_NP to_TO increase_VB sensitivity_NN ;_: in_IN all_DT other_JJ experiments_NNS 10,000_CD cells_NNS were_VBD analyzed_VBN ._SENT Mutation_NN of_IN Reverse_NP Transcriptase_NP Active_NP Site_NP ._SENT |_SYM Quikchange_NP site-directed_JJ mutagenesis_NN (_( Stratagene_NP )_) was_VBD performed_VBN according_VBG to_TO manufacturer_NN 's_POS protocols_NNS by_IN using_VBG p8.91_JJ HIV-1_NP gag-pol_NP expression_NN vector_NN and_CC oligonucleotides_NNS forward_RB GT141_NP CAATACATGGAAGATTTGTATGTAGGATC_NP and_CC reverse_VB GT142_NP GATCCTACATACAAATCTTCCATGTATTG_NP ._SENT The_DT conserved_VBN YMDD_NN motif_NN was_VBD changed_VBN to_TO YMED_NP ._SENT TaqMan_NP Quantitative_NP PCR_NP of_IN Viral_NP DNA_NP ._SENT |_SYM As_RB in_IN the_DT abrogation_NN assays_NNS ,_, 105_CD cells_NNS were_VBD infected_VBN in_IN six-well_NN plates_NNS in_IN triplicate_NN ._SENT Four_CD hours_NNS after_IN the_DT second_JJ infection_NN total_NN DNA_NN was_VBD extracted_VBN by_IN using_VBG a_DT DNeasy_NP kit_NN (_( Qiagen_NP ,_, Chatsworth_NP ,_, CA_NP )_) from_IN two_CD samples_NNS ._SENT The_DT third_JJ sample_NN was_VBD subjected_VBN to_TO FACS_NP analysis_NN 48_CD h_NN later_RBR to_TO measure_VB infection_NN ._SENT DNA_NP (_( 100_CD ng_NNS )_) was_VBD subjected_VBN to_TO TaqMan_NP quantitative_JJ PCR_NP essentially_RB as_RB described_VBN by_IN using_VBG TaqMan_NP 2x_NP quantitative_JJ PCR_NP buffer_NN (_( Applied_NP Biosystems_NP )_) with_IN primers_NNS and_CC probe_NN at_IN 300_CD nM_NN and_CC 150_CD nM_NN ,_, respectively_RB ._SENT Primer_NN and_CC probe_NN sequences_NNS were_VBD homologous_JJ to_TO GFP_NP and_CC are_VBP as_RB follows_VBZ :_: GFP_JJ forward_JJ CAACAGCCACAACGTCTATATCAT_NN ,_, GFP_NP reverse_NN ,_, ATGTTGTGGCGGATCTTGAAG_NP ,_, Probe_NP 5'-FAM-CCGACAAGCAGAAGAACGGCATCAA-3'TAMRA_NP ._SENT To_TO measure_VB infection_NN by_IN retrovirus_NN we_PP made_VBD high-titer_NN retroviral_JJ vectors_NNS encoding_VBG marker_NN genes_NNS ._SENT These_DT vectors_NNS were_VBD pseudotyped_JJ with_IN the_DT pantropic_JJ VSV-G_NN unless_IN otherwise_RB stated_VBN ,_, and_CC are_VBP designated_VBN by_IN a_DT code_NN describing_VBG the_DT virus_NN ,_, HIV_NP and_CC SIVmac_NP ,_, and_CC the_DT marker_NN gene_NN ,_, eGFP_NN ,_, LacZ_NP ,_, and_CC puro_NN ._SENT Saturation_NN of_IN HIV-1_NP Restriction_NP in_IN Monkey_NP Cells_NP ._SENT |_SYM Abrogation_NP assays_NNS were_VBD performed_VBN on_IN cells_NNS from_IN rhesus_NN macaque_NN (_( FRhK4_NP and_CC LLC-MK2_NP )_) and_CC owl_NN monkey_NN (_( OMK_NP )_) because_IN cells_NNS from_IN these_DT species_NNS have_VBP been_VBN shown_VBN to_TO be_VB refractory_JJ to_TO HIV-1_JJ infection_NN ._SENT We_PP also_RB tested_VBD African_JJ green_JJ monkey_NN CV1_JJ cells_NNS and_CC human_JJ TE671_JJ cells_NNS ,_, which_WDT are_VBP relatively_RB permissive_JJ ,_, and_CC rabbit_VB SIRC_NP cells_NNS ,_, which_WDT are_VBP highly_RB resistant_JJ to_TO VSV-pseudotyped_NP HIV-eGFP_NP vector_NN ._SENT We_PP were_VBD testing_VBG for_IN an_DT increase_NN in_IN HIV-eGFP_NP titer_NN after_IN an_DT initial_JJ exposure_NN to_TO HIV-puro_NP or_CC SIV-LacZ_NP had_VBD saturated_VBN the_DT available_JJ restriction_NN factor_NN ._SENT Cells_NNS were_VBD exposed_VBN to_TO high_JJ doses_NNS of_IN HIV-puro_NP or_CC SIV-LacZ_NP ,_, and_CC then_RB exposed_VBN to_TO a_DT low_JJ dose_NN of_IN HIV-eGFP_NP ._SENT The_DT titer_NN of_IN HIV-eGFP_NP was_VBD increased_VBN by_IN 10_CD times_NNS (_( CV1_NP )_) ,_, even_RB though_IN these_DT cells_NNS are_VBP relatively_RB permissive_JJ ,_, 20_CD times_NNS (_( FRhK4_NP )_) ,_, 3_CD times_NNS (_( LLC-MK2_NP )_) ,_, or_CC 30_CD times_NNS (_( OMK_NP )_) by_IN preexposure_NN to_TO HIV_NP but_CC not_RB when_WRB preexposed_JJ to_TO SIVmac_NP vectors_NNS ._SENT HIV-eGFP_NP titer_NN was_VBD increased_VBN by_IN a_DT small_JJ amount_NN (_( 5-fold_NN )_) on_IN CV1_JJ cells_NNS after_IN exposure_NN to_TO SIVmac_NP and_CC also_RB on_IN SIRC_NP cells_NNS after_IN exposure_NN to_TO either_DT SIVmac_NP or_CC HIV_NP vectors_NNS (_( 4-_CD and_CC 10-fold_NN ,_, respectively_RB )_) ._SENT Figure_NP 1_CD |_SYM (_( A_NP )_) Abrogation_NP of_IN HIV-1_NP restriction_NN in_IN owl_NN monkey_NN cells_NNS ._SENT (_( A_NP )_) Abrogation_NP of_IN HIV-1_NP restriction_NN in_IN owl_NN monkey_NN cells_NNS ._SENT FACS_NP plots_NNS of_IN side_NN scatter_NN versus_IN GFP_NP fluorescence_NN are_VBP shown_VBN ._SENT Owl_NN monkey_NN cells_NNS are_VBP uninfected_JJ (_( i_NP )_) ,_, infected_VBN with_IN 105_CD TE671_JJ i.u._NN of_IN HIV-eGFP_NP (_( ii_NP )_) ,_, or_CC exposed_VBD to_TO 107_CD TE671_NP i.u._NP of_IN HIV-puro_NP for_IN 4_CD h_NN ,_, washed_VBN ,_, and_CC then_RB infected_VBN with_IN 105_CD TE671_JJ i.u._NN of_IN HIV-eGFP_NP ._SENT Region_NN of_IN GFP-positive_JJ cells_NNS (_( R1_NP )_) and_CC percentages_NNS of_IN positive_JJ cells_NNS are_VBP indicated_VBN ._SENT (_( B_NP )_) Abrogation_NP of_IN HIV_NP restriction_NN in_IN monkey_NN and_CC rabbit_NN cells_NNS ._SENT Cells_NNS (_( 105_CD )_) were_VBD exposed_VBN to_TO 5_CD x_SYM 106_CD TE671_JJ i.u._NN of_IN either_DT HIV-puro_NP (_( square_NN )_) or_CC SIV-LacZ_NP ,_, incubated_VBN for_IN 4_CD h_NN ,_, washed_VBN ,_, and_CC then_RB exposed_VBN to_TO 104_CD (_( TE671_NP )_) ,_, 105_NP (_( OMK_NP ,_, FRhK4_NP )_) ,_, 5_CD x_SYM 104_CD (_( LLC-MK2_NP ,_, CV1_NP )_) ,_, and_CC 5_CD x_NN 106_CD (_( SIRC_NP )_) TE671_NP i.u._NP of_IN HIV-eGFP_NP ._SENT Percentage_NN infection_NN was_VBD measured_VBN by_IN analysis_NN of_IN eGFP_NN expression_NN 48_CD h_NN later_RBR by_IN FACS_NP ._SENT Fold_NN abrogation_NN is_VBZ calculated_VBN by_IN dividing_VBG the_DT increased_VBN percentage_NN infection_NN after_IN abrogation_NN by_IN unabrogated_JJ control_NN HIV-eGFP_NP infection_NN ._SENT Typically_RB 1_CD --_: 5_CD %_NN of_IN unabrogated_JJ controls_NNS were_VBD infected_VBN ._SENT Errors_NNS are_VBP standard_JJ error_NN of_IN the_DT mean_NN of_IN three_CD independent_JJ experiments_NNS ._SENT Kinetics_NNS of_IN Strong_JJ Restriction_NP Are_NP Multihit_NP at_IN High_NP Virus_NP Dose_NP ._SENT |_SYM Restriction_NP of_IN MLV_NP in_IN mice_NNS by_IN Fv1_NP and_CC in_IN humans_NNS by_IN Ref1_NP has_VBZ been_VBN shown_VBN to_TO result_VB in_IN two-hit_NN kinetics_NNS of_IN infection_NN at_IN high_JJ virus_NN doses_NNS ,_, which_WDT means_VBZ that_IN the_DT chance_NN of_IN a_DT cell_NN being_VBG infected_VBN is_VBZ related_VBN to_TO the_DT square_NN of_IN the_DT virus_NN concentration_NN and_CC the_DT slope_NN of_IN a_DT log(_JJ %_NN infection_NN )_) vs._CC log(virus_NN dose_NN )_) plot_NN is_VBZ 2_CD ._SENT To_TO investigate_VB infection_NN kinetics_NNS of_IN HIV_NP restriction_NN ,_, serial_JJ dilutions_NNS of_IN HIV-eGFP_NP were_VBD titrated_VBN onto_IN permissive_JJ and_CC nonpermissive_JJ cells_NNS ._SENT We_PP were_VBD seeking_VBG a_DT characteristic_JJ bend_NN in_IN the_DT titration_NN curve_NN ,_, which_WDT appears_VBZ as_IN a_DT restricting_VBG virus_NN begins_VBZ to_TO soak_VB up_RP factors_NNS that_WDT inhibit_VBP infection_NN ,_, and_CC a_DT slope_NN of_IN 2_CD or_CC greater_JJR at_IN high_JJ virus_NN dose_NN ._SENT Fig._NN A_DT shows_VBZ a_DT titration_NN curve_NN of_IN HIV-eGFP_NP on_IN OMK_NP ,_, and_CC Fig._NN B_NN shows_VBZ FRhK4_NP and_CC LLC-MK2_NP cells_NNS ._SENT The_DT characteristic_JJ bend_NN ,_, indicating_VBG a_DT switch_NN from_IN one-_NN to_TO multiple-hit_NN kinetics_NNS ,_, can_MD be_VB seen_VBN as_RB between_IN 1_CD %_NN and_CC 10_CD %_NN cells_NNS are_VBP infected_VBN ._SENT Rhesus_NN macaque_NN LLC-MK2_JJ cells_NNS are_VBP infected_VBN 10_CD times_NNS more_RBR efficiently_RB than_IN FRhK4_NP cells_NNS ,_, show_VBP no_RB bend_VB in_IN the_DT titration_NN curve_NN ,_, and_CC are_VBP not_RB made_VBN significantly_RB more_RBR permissive_JJ by_IN abrogation_NN ._SENT Two-hit_NN kinetics_NNS was_VBD also_RB seen_VBN when_WRB FRhK4_NP and_CC OMK_NP cells_NNS were_VBD infected_VBN with_IN HIV-eGFP_NP pseudotyped_NN with_IN MLV_NP amphotropic_JJ envelope_NN ,_, demonstrating_VBG that_IN restriction_NN is_VBZ not_RB specific_JJ to_TO VSV-G_NP (_( data_NN not_RB shown_VBN )_) ._SENT Fig._NN C_NP shows_VBZ titration_NN of_IN SIV-eGFP_NP onto_IN OMK_NP ,_, LLC-MK2_NP ,_, and_CC FRhK4_NP cells_NNS ._SENT These_DT cells_NNS do_VBP not_RB restrict_VB SIVmac_NP and_CC show_VB single-hit_NN kinetics_NNS of_IN infection_NN ._SENT Figure_NP 2_CD |_SYM Titration_NN of_IN lentiviral_JJ vectors_NNS onto_IN restricting_VBG cells_NNS ._SENT Titration_NN of_IN lentiviral_JJ vectors_NNS onto_IN restricting_VBG cells_NNS ._SENT Two-fold_NN serial_NN dilutions_NNS of_IN HIV-eGFP_NP were_VBD titrated_VBN onto_IN 105_CD OMK_NP cells_NNS (_( A_NP )_) ,_, LLC-MK2_NP and_CC FRhK4_NP (_( circle_NN )_) cells_NNS from_IN rhesus_NN macaque_NN (_( B_NP )_) ._SENT (_( C_NP )_) Two-fold_NN serial_NN dilutions_NNS of_IN SIV-LacZ_NP were_VBD titrated_VBN onto_IN OMK_NP (_( circle_NN )_) ,_, FRhK4_NP ,_, and_CC LLC-MK2_NP (_( square_JJ )_) cells_NNS ._SENT Two-fold_NN serial_NN dilutions_NNS of_IN HIV-eGFP_NP (_( circle_NN )_) or_CC SIV-eGFP_NP were_VBD titrated_VBN onto_IN African_JJ green_JJ monkey_NN CV1_JJ cells_NNS (_( D_NP )_) or_CC rabbit_VB SIRC_NP cells_NNS (_( E_NP )_) ._SENT Results_NNS are_VBP representative_JJ of_IN two_CD independent_JJ experiments_NNS ._SENT Lines_NNS are_VBP guides_NNS for_IN slopes_NNS of_IN 1_CD and_CC 2_CD ._SENT Fig._NN D_NP shows_VBZ titration_NN of_IN HIV-eGFP_NP and_CC SIV-eGFP_NP onto_IN CV1_NP cells_NNS ._SENT Although_IN HIV-eGFP_NP shows_VBZ single-hit_NN kinetics_NNS ,_, the_DT slope_NN for_IN the_DT SIV-eGFP_NP titration_NN curve_NN was_VBD higher_JJR than_IN 1_CD ,_, suggesting_VBG stronger_JJR restriction_NN for_IN SIVmac_NP infection_NN ._SENT Abrogation_NN of_IN this_DT restriction_NN by_IN both_DT HIV_NP and_CC SIVmac_NP is_VBZ further_RBR examined_VBN below_IN (_( see_VB Fig._NN )_) ._SENT Low_JJ Permissivity_NN to_TO HIV-eGFP_NP Is_VBZ Partly_RB Due_JJ to_TO Saturable_JJ Restriction_NN in_IN Rabbit_NP SIRC_NP Cells_NP ._SENT |_SYM Rabbit_NP SIRC_NP cells_NNS are_VBP 3_CD --_: 4_CD logs_NNS less_RBR infectable_JJ by_IN HIV_NP vectors_NNS compared_VBN with_IN human_JJ TE671_JJ cells_NNS ._SENT In_IN Fig._NN E_NN ,_, these_DT cells_NNS are_VBP infected_VBN with_IN SIV-eGFP_NP and_CC HIV-eGFP_NP ._SENT Rabbit_VB SIRC_NP cells_NNS are_VBP permissive_JJ for_IN SIV-eGFP_NP and_CC single-hit_NN kinetics_NNS are_VBP seen_VBN ._SENT At_IN very_RB high_JJ doses_NNS of_IN HIV-eGFP_NP ,_, a_DT switch_NN to_TO two-hit_NN kinetics_NNS occurs_VBZ ,_, but_CC SIRC_NP cells_NNS remain_VBP at_IN least_JJS 3_CD logs_NNS less_RBR permissive_JJ to_TO HIV_NP than_IN SIVmac_NP ._SENT We_PP conclude_VBP that_IN the_DT block_NN in_IN SIRC_NP cells_NNS is_VBZ only_RB partly_RB due_JJ to_TO a_DT saturable_JJ restriction_NN factor_NN ._SENT Requirement_NN for_IN DNA_NP Synthesis_NP and_CC Decay_NP of_IN Abrogation_NP ._SENT |_SYM Abrogation_NP of_IN restriction_NN should_MD be_VB mediated_VBN by_IN the_DT incoming_JJ virus_NN components_NNS ,_, most_RBS likely_JJ viral_JJ proteins_NNS ._SENT Restriction_NN could_MD be_VB associated_VBN with_IN the_DT process_NN of_IN reverse_JJ transcription_NN of_IN the_DT viral_JJ DNA_NN because_IN it_PP seemed_VBD to_TO occur_VB at_IN or_CC before_IN DNA_NN synthesis_NN (_( see_VB Fig._NN )_) ._SENT To_TO test_VB whether_IN DNA_NN synthesis_NN was_VBD required_VBN in_IN the_DT abrogating_VBG vector_NN we_PP prepared_VBD p8.91_JJ HIV-1_NP gag-pol_NP expression_NN vector_NN with_IN a_DT D185E_JJ change_NN in_IN the_DT highly_RB conserved_VBN YMD185D_JJ motif_NN of_IN the_DT reverse_JJ transcriptase_NN active_JJ site_NN ._SENT This_DT mutation_NN completely_RB blocks_VBZ the_DT ability_NN of_IN the_DT virus_NN to_TO reverse_VB transcribe_VB but_CC is_VBZ unlikely_JJ to_TO have_VB any_DT physical_JJ effect_NN on_IN retroviral_JJ core_NN structure_NN ._SENT HIV-eGFP_NP was_VBD prepared_VBN with_IN this_DT construct_NN and_CC used_VBN to_TO abrogate_VB restriction_NN in_IN OMK_NP and_CC FRhK4_NP cells_NNS ._SENT This_DT virus_NN produced_VBD no_DT infection_NN on_IN TE671_JJ cells_NNS at_IN high_JJ dose_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Fig._NN A_NP shows_VBZ that_IN this_DT virus_NN was_VBD able_JJ to_TO abrogate_VB infection_NN to_TO a_DT similar_JJ degree_NN as_IN wild-type_NP HIV-puro_NP (_( Fig._NN B_NN )_) ._SENT Fig._NN B_NN also_RB shows_VBZ that_IN restriction_NN is_VBZ about_RB 20-_CD and_CC 30-fold_NN for_IN FRhK4_NP and_CC OMK_NP cells_NNS ,_, respectively_RB ,_, and_CC that_IN 107_CD TE671_JJ i.u._JJ /ml_NN of_IN HIV-puro_NP are_VBP required_VBN for_IN maximum_JJ abrogation_NN of_IN restriction_NN ._SENT We_PP have_VBP measured_VBN the_DT ratio_NN of_IN infectious_JJ dose_NN to_TO physical_JJ particles_NNS in_IN vector_NN preparations_NNS similar_JJ to_TO those_DT used_VBN here_RB and_CC estimate_VBP that_IN 2_CD x_NN 104_CD particles_NNS per_IN cell_NN are_VBP required_VBN to_TO abrogate_VB HIV-1_JJ restriction_NN ._SENT Figure_NP 3_CD |_SYM Abrogation_NN by_IN reverse_JJ transcriptase_NN mutant_NN and_CC time_NN course_NN of_IN abrogation_NN decay_NN ._SENT Abrogation_NN by_IN reverse_JJ transcriptase_NN mutant_NN and_CC time_NN course_NN of_IN abrogation_NN decay_NN ._SENT OMK_NP (_( circle_NN )_) or_CC FRhK4_NP cells_NNS (_( 105_CD )_) were_VBD exposed_VBN to_TO serial_JJ dilutions_NNS of_IN reverse_JJ transcriptase-defective_JJ HIV-eGFP_NP D185E_NP (_( A_NP )_) or_CC wild-type_NP HIV-puro_NP (_( B_NP )_) for_IN 4_CD h._NP Cells_NP were_VBD washed_VBN and_CC exposed_VBN to_TO 105_CD TE671_NP i.u._NP of_IN HIV-eGFP_NP ._SENT Percentage_NN infection_NN was_VBD measured_VBN by_IN analysis_NN of_IN eGFP_NN expression_NN 48_CD h_NN later_RBR by_IN FACS_NP ._SENT Fold_NN abrogation_NN is_VBZ calculated_VBN by_IN dividing_VBG the_DT increased_VBN percentage_NN infection_NN after_IN abrogation_NN by_IN unabrogated_JJ control_NN HIV-eGFP_NP infection_NN ._SENT About_RB 1_CD %_NN of_IN unabrogated_JJ controls_NNS typically_RB were_VBD infected_VBN ._SENT p24_JJ concentrations_NNS of_IN wild-type_NN and_CC mutant_JJ supernatants_NNS were_VBD similar_JJ with_IN around_RB 500_CD ng_NNS /ml_NN corresponding_JJ to_TO a_DT titer_NN of_IN 107_CD TE671_JJ i.u._JJ wild-type_NN HIV-puro_NP ._SENT OMK_NP cells_NNS (_( 105_CD )_) were_VBD exposed_VBN to_TO 107_CD TE671_NP i.u._NP of_IN HIV-puro_NP for_IN 4_CD h_NN ,_, washed_VBN ,_, and_CC exposed_VBD to_TO 105_CD TE671_NP i.u._NP of_IN HIV-eGFP_NP at_IN 4-h_JJ intervals_NNS (_( C_NP )_) ._SENT Percentage_NN infection_NN and_CC fold_NN abrogation_NN were_VBD determined_VBN as_RB above_RB ._SENT Data_NNS are_VBP representative_JJ of_IN two_CD independent_JJ experiments_NNS ._SENT To_TO investigate_VB the_DT stability_NN of_IN the_DT abrogation_NN of_IN restriction_NN we_PP performed_VBD the_DT following_VBG experiment_NN ._SENT OMK_NN cells_NNS were_VBD exposed_VBN to_TO high-dose_NN HIV-puro_NP for_IN 4_CD h_NN ,_, washed_VBN ,_, and_CC then_RB exposed_VBN to_TO 105_CD TE671_NP i.u._NP of_IN HIV-eGFP_NP at_IN various_JJ later_JJR time_NN points_NNS ._SENT HIV-eGFP_JJ titer_NN after_IN abrogation_NN linearly_RB decreases_VBZ with_IN a_DT half-life_NN of_IN around_RB 9_CD h_NN (_( Fig._NN C_NP )_) ._SENT SIV_NP Restriction_NP and_CC Its_PP$ Abrogation_NN by_IN Both_DT HIV_NP and_CC SIV_NP in_IN African_NP Green_NP Monkey_NP CV1_NP Cells_NP ._SENT |_SYM CV1_JJ data_NNS in_IN Fig._NN B_NN ,_, showing_VBG that_DT exposure_NN to_TO SIV-LacZ_NP was_VBD able_JJ to_TO increase_VB the_DT titre_NN of_IN HIV-eGFP_NP ,_, implied_VBD that_IN there_EX is_VBZ a_DT factor_NN in_IN CV1_JJ cells_NNS restricting_VBG both_DT HIV1_NP and_CC SIVmac_NP ._SENT Furthermore_RB ,_, a_DT steep_JJ titration_NN curve_NN suggested_VBD stronger_JJR restriction_NN of_IN SIVmac_NP than_IN HIV_NP in_IN these_DT cells_NNS ._SENT To_TO examine_VB this_DT possibility_NN further_RBR we_PP titrated_VBD HIV-puro_NP and_CC SIV-LacZ_NP onto_IN CV1_NP cells_NNS and_CC then_RB infected_VBN them_PP with_IN a_DT fixed_VBN dose_NN of_IN SIV-eGFP_NP ._SENT High_JJ doses_NNS of_IN either_DT HIV_NP or_CC SIVmac_NP vector_NN were_VBD able_JJ to_TO increase_VB the_DT titer_NN of_IN SIV-eGFP_NP by_IN up_RB to_TO 30-fold_NN ._SENT Figure_NP 4_CD |_SYM Abrogation_NN of_IN restriction_NN of_IN SIV-eGFP_NP by_IN SIV-LacZ_NP and_CC HIV-puro_NP in_IN African_JJ green_JJ monkey_NN CV1_JJ cells_NNS ._SENT Abrogation_NN of_IN restriction_NN of_IN SIV-eGFP_NP by_IN SIV-LacZ_NP and_CC HIV-puro_NP in_IN African_JJ green_JJ monkey_NN CV1_JJ cells_NNS ._SENT TE671_NP ,_, LLC-MK2_NP (_( circle_NN )_) ,_, OMK_NP (_( x_LS )_) ,_, or_CC CV1_JJ cells_NNS were_VBD exposed_VBN to_TO 5_CD x_SYM 106_CD TE671_NP i.u._NP of_IN SIV-LacZ_NP or_CC 5_CD x_SYM 106_CD TE671_NP i.u_NP HIV-puro_NP (_( CV1_NP only_RB )_) for_IN 4_CD h_NN ,_, washed_VBN ,_, and_CC exposed_VBD to_TO 5_CD x_SYM 104_CD i.u._NN of_IN SIV-eGFP_NP ._SENT Percentage_NN infection_NN was_VBD measured_VBN by_IN analysis_NN of_IN eGFP_NN expression_NN 48_CD h_NN later_RBR by_IN FACS_NP ._SENT Fold_NN abrogation_NN is_VBZ calculated_VBN by_IN dividing_VBG the_DT increased_VBN percentage_NN infection_NN after_IN abrogation_NN by_IN unabrogated_JJ control_NN HIV-eGFP_NP infection_NN ._SENT Approximately_RB 1_CD %_NN of_IN unabrogated_JJ monkey_NN controls_NNS and_CC 10_CD %_NN of_IN human_JJ TE671_JJ controls_NNS typically_RB were_VBD infected_VBN ._SENT Data_NNS are_VBP representative_JJ of_IN two_CD independent_JJ experiments_NNS ._SENT Reverse_JJ Transcription_NN Is_VBZ Blocked_JJ in_IN Restricted_NP Cells_NP ._SENT |_SYM Ref1_JJ restriction_NN of_IN mouse_NN viruses_NNS in_IN human_JJ cells_NNS occurs_VBZ at_IN or_CC before_IN reverse_JJ transcription_NN ._SENT To_TO determine_VB whether_IN reverse_JJ transcription_NN of_IN HIV_NP and_CC SIV_NP is_VBZ inhibited_VBN in_IN restricting_VBG monkeys_NNS we_PP performed_VBD quantitative_JJ PCR_NP to_TO measure_VB viral_JJ DNA_NN synthesis_NN on_RB extracts_VBZ from_IN cells_NNS 4_CD h_NN after_IN infection_NN ._SENT Equal_JJ virus_NN doses_NNS (_( 105_CD TE671_NP i.u._NP )_) were_VBD used_VBN to_TO infect_VB a_DT fixed_VBN number_NN of_IN cells_NNS (_( 105_CD )_) with_IN and_CC without_IN preexposure_NN to_TO an_DT abrogating_VBG virus_NN HIV-puro_NP or_CC SIV-LacZ_NP ._SENT This_DT assay_NN indicates_VBZ the_DT difference_NN between_IN DNA_NN synthesis_NN between_IN restricted_JJ and_CC nonrestricted_JJ infection_NN in_IN the_DT same_JJ cell_NN line_NN and_CC differences_NNS in_IN reverse_JJ transcription_NN between_IN species_NNS ._SENT In_IN agreement_NN with_IN previous_JJ studies_NNS the_DT block_NN to_TO infection_NN in_IN macaque_NN cells_NNS is_VBZ before_RB reverse_JJ transcription_NN ._SENT Figure_NP 5_CD |_SYM Quantitative_NP PCR_NP of_IN restricted_JJ and_CC unrestricted_JJ infection_NN ._SENT Quantitative_JJ PCR_NP of_IN restricted_JJ and_CC unrestricted_JJ infection_NN ._SENT FRHK4_NP ,_, OMK_NP ,_, CV1_NP ,_, or_CC TE671_JJ cells_NNS (_( 105_CD )_) were_VBD infected_VBN preexposed_JJ to_TO 107_CD TE671_NP i.u._NP of_IN HIV-puro_NP for_IN 4_CD h_NN (_( square_JJ )_) or_CC left_VBD unexposed_JJ ,_, washed_JJ ,_, and_CC then_RB infected_VBN with_IN 5_CD x_SYM 104_CD TE671_NP i.u._NP of_IN HIV-eGFP_NP ._SENT For_IN SIV_NP on_IN CV1_NP cells_NNS 106_CD TE671_JJ i.u._NN of_IN HIV-puro_NP (_( square_NN )_) or_CC 106_CD TE671_JJ i.u._NN of_IN SIV-LacZ_NP (_( striped_JJ bar_NN )_) was_VBD used_VBN to_TO abrogate_VB and_CC then_RB 5_CD x_SYM 104_CD i.u._NN of_IN SIV-eGFP_NP was_VBD used_VBN to_TO infect_VB cells_NNS ._SENT Four_CD hours_NNS after_IN the_DT second_JJ round_NN of_IN infection_NN ,_, total_JJ DNA_NN was_VBD extracted_VBN and_CC 100_CD ng_NNS was_VBD subjected_VBN to_TO quantitative_JJ PCR_NP (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT Viral_JJ template_NN copy_NN number_NN per_IN 100_CD ng_NNS of_IN total_JJ DNA_NN was_VBD calculated_VBN by_IN reference_NN to_TO a_DT standard_JJ curve_NN ._SENT Approximately_RB 1_CD --_: 10_CD %_NN of_IN unabrogated_JJ monkey_NN control_NN cells_NNS were_VBD infected_VBN ,_, and_CC 35_CD %_NN of_IN TE671_JJ controls_NNS ._SENT Data_NNS are_VBP representative_JJ of_IN two_CD independent_JJ experiments_NNS with_IN duplicate_JJ PCR_NP ._SENT Errors_NNS are_VBP standard_JJ error_NN of_IN the_DT mean_NN ._SENT Parallel_JJ samples_NNS were_VBD analyzed_VBN by_IN FACS_NP ,_, and_CC levels_NNS of_IN restriction_NN were_VBD similar_JJ to_TO those_DT in_IN Figs._NP and_NP ._SENT Saturable_JJ factors_NNS that_WDT restrict_VBP MLV_NP in_IN mice_NNS (_( Fv1_NP )_) and_CC humans_NNS (_( Ref1_NP )_) have_VBP been_VBN described_VBN ._SENT Although_IN rhesus_NN macaques_NNS have_VBP long_RB been_VBN known_VBN to_TO have_VB very_RB low_JJ permissivity_NN for_IN HIV-1_NP ,_, with_IN a_DT viral_JJ determinant_NN in_IN gag-pol_NP ,_, the_DT mechanism_NN of_IN the_DT block_NN to_TO infection_NN has_VBZ remained_VBN unclear_JJ ._SENT These_DT data_NNS demonstrate_VBP the_DT presence_NN of_IN a_DT saturable_JJ factor_NN or_CC factors_NNS able_JJ to_TO restrict_VB HIV-1_NP and_CC SIVmac251_NP in_IN simian_JJ cell_NN lines_NNS ._SENT Fig._NN shows_VBZ that_IN the_DT titer_NN of_IN HIV-eGFP_NP vector_NN can_MD be_VB increased_VBN in_IN cells_NNS from_IN rhesus_NN macaque_NN ,_, owl_NN monkey_NN ,_, and_CC African_JJ green_JJ monkeys_NNS by_IN preexposure_NN to_TO HIV-puro_NP ._SENT Rhesus_NN macaques_NNS remain_VBP the_DT major_JJ primate_NN experimental_JJ model_NN ,_, essential_JJ in_IN the_DT production_NN of_IN an_DT HIV_NP vaccine_NN ._SENT The_DT presence_NN of_IN a_DT restriction_NN factor_NN against_IN HIV-1_NP in_IN macaque_NN may_MD explain_VB the_DT inability_NN of_IN HIV-1_NP to_TO cause_VB disease_NN in_IN these_DT monkeys_NNS ._SENT Where_WRB a_DT virus_NN is_VBZ restricted_VBN more_RBR than_IN 20-fold_JJ ,_, multiple-hit_JJ kinetics_NNS are_VBP seen_VBN at_IN high_JJ virus_NN dose_NN ,_, which_WDT indicates_VBZ the_DT factor_NN is_VBZ being_VBG soaked_VBN up_RP by_IN high-titer_NN incoming_JJ virus_NN ._SENT Two-hit_NN kinetics_NNS implies_VBZ that_DT exposure_NN to_TO an_DT initial_JJ restricted_JJ virion_NN facilitates_VBZ infection_NN by_IN a_DT second_JJ restricted_JJ virion_NN ._SENT In_IN this_DT case_NN the_DT probability_NN of_IN infection_NN is_VBZ related_VBN to_TO the_DT square_NN of_IN the_DT concentration_NN of_IN the_DT virus_NN ,_, and_CC the_DT slope_NN of_IN a_DT log(infection)_NN versus_CC log(virus_NN dose_NN )_) is_VBZ 2_CD ._SENT These_DT properties_NNS of_IN restriction_NN of_IN retroviral_JJ infection_NN are_VBP reminiscent_JJ of_IN MLV_NP restriction_NN by_IN Ref1_NP in_IN human_JJ cells_NNS and_CC Fv1_JJ in_IN mouse_NN cells_NNS ._SENT The_DT abrogation_NN of_IN HIV_NP restriction_NN does_VBZ not_RB require_VB reverse_JJ transcription_NN of_IN abrogating_VBG virus_NN particles_NNS (_( Fig._NN A_NP )_) ,_, and_CC the_DT activity_NN after_IN exposure_NN to_TO abrogating_VBG virus_NN has_VBZ a_DT half-life_NN of_IN 9_CD h_NN (_( Fig._NN C_NP )_) ._SENT Rhesus_NN macaque_NN LLC-MK2_JJ cells_NNS only_RB weakly_RB restrict_VB HIV-1_NP (_( Figs._NP and_NP )_) ,_, and_CC consequently_RB ,_, HIV-eGFP_NP has_VBZ a_DT 10-fold_NN higher_JJR titer_NN on_IN these_DT cells_NNS than_IN on_IN FRhK4_NP ._SENT Both_DT FRhK4_NP cells_NNS ,_, which_WDT restrict_VBP ,_, and_CC LLC-MK2_NP ,_, which_WDT do_VBP not_RB ,_, are_VBP derived_VBN from_IN Macaca_NP mulatta_NP kidney_NN ._SENT LLC-MK2_JJ cells_NNS may_MD have_VB lost_VBN expression_NN of_IN the_DT restriction_NN factor_NN ._SENT A_DT precedent_NN exists_VBZ for_IN cell_NN lines_NNS from_IN restricting_VBG mice_NNS lacking_VBG restriction_NN in_IN SC1_JJ cells_NNS and_CC 3T3FL_JJ cells_NNS ._SENT Further_JJR analysis_NN of_IN factor_NN expression_NN will_MD require_VB isolation_NN of_IN the_DT gene_NN or_CC genes_NNS responsible_JJ ._SENT Rabbit_VB SIRC_NP cells_NNS are_VBP resistant_JJ to_TO HIV-eGFP_NP but_CC not_RB SIV-eGFP_NP (_( Fig._NN D_NP )_) ._SENT The_DT titer_NN of_IN HIV-eGFP_NP is_VBZ increased_VBN 10-fold_NN by_IN exposure_NN to_TO high-dose_NN HIV-puro_NP ,_, and_CC HIV-eGFP_NP infection_NN has_VBZ multiple-hit_JJ kinetics_NNS at_IN a_DT high_JJ virus_NN dose_NN ._SENT Poor_NP HIV_NP infection_NN in_IN SIRC_NP cells_NNS is_VBZ therefore_RB partly_RB due_JJ to_TO a_DT saturable_JJ restricting_VBG factor(s_NNS )_) ._SENT However_RB ,_, the_DT low_JJ titer_NN of_IN HIV_NP vector_NN on_IN SIRC_NP cells_NNS may_MD be_VB largely_RB due_JJ to_TO an_DT inability_NN of_IN HIV_NP to_TO use_VB rabbit_NN host_NN cofactors_NNS ._SENT Difference_NN in_IN retroviral_JJ titer_NN between_IN cells_NNS from_IN different_JJ species_NNS are_VBP likely_JJ to_TO be_VB dependent_JJ to_TO some_DT degree_NN on_IN cellular_JJ cofactor_NN compatibility_NN ._SENT Poor_JJ infection_NN because_IN of_IN lack_NN of_IN compatibility_NN is_VBZ not_RB likely_JJ to_TO be_VB saturable_JJ by_IN preexposure_NN to_TO retrovirus_NN ._SENT The_DT data_NNS presented_VBD here_RB show_VB that_IN restriction_NN factors_NNS are_VBP more_RBR common_JJ than_IN previously_RB thought_VBN ._SENT The_DT target_NN for_IN restriction_NN is_VBZ likely_JJ to_TO reside_VB in_IN the_DT capsid_NN of_IN the_DT lentivirus_NN ._SENT It_PP has_VBZ been_VBN shown_VBN that_IN an_DT SIVmac_NP with_IN an_DT HIV-1_NP capsid-p2_NN domain_NN has_VBZ the_DT restriction_NN phenotype_NN of_IN HIV-1_NP rather_RB than_IN SIVmac_NP and_CC was_VBD able_JJ to_TO replicate_VB in_IN human_JJ cells_NNS and_CC not_RB macaque_NN peripheral_JJ blood_NN mononuclear_JJ cells_NNS ._SENT Furthermore_RB ,_, the_DT Fv1_JJ /Ref1_JJ target_NN sequence_NN is_VBZ in_IN the_DT capsid_NN of_IN MLV_NP ._SENT Cells_NNS from_IN African_JJ green_JJ monkey_NN are_VBP able_JJ to_TO restrict_VB SIVmac_NP as_RB well_RB as_IN HIV_NP ,_, and_CC reciprocal_JJ saturation_NN of_IN the_DT factor_NN by_IN SIVmac_NP or_CC HIV_NP indicates_VBZ that_IN a_DT single_JJ factor_NN is_VBZ responsible_JJ ._SENT The_DT fact_NN that_IN a_DT restriction_NN factor_NN can_MD hit_VB more_JJR than_IN one_CD virus_NN suggests_VBZ that_IN the_DT selecting_VBG virus_NN ,_, which_WDT forced_VBD the_DT host_NN to_TO acquire_VB this_DT restriction_NN factor_NN ,_, may_MD be_VB at_IN least_JJS as_RB unrelated_JJ to_TO HIV_NP or_CC SIVmac_NP as_IN they_PP are_VBP to_TO each_DT other_JJ ._SENT Although_IN Fv1_NP has_VBZ approximately_RB 60_CD %_NN sequence_NN homology_NN with_IN gag_NN from_IN HERV-L_NP and_CC MuERV-L_NP ,_, it_PP is_VBZ only_RB distantly_RB related_VBN to_TO MLV_NP ,_, which_WDT suggests_VBZ that_DT lentiviral_JJ restriction_NN is_VBZ a_DT function_NN of_IN retrovirus-like_JJ sequences_NNS unrelated_JJ to_TO lentiviruses_NNS themselves_PP ._SENT We_PP have_VBP shown_VBN that_IN cells_NNS from_IN African_JJ green_JJ monkey_NN are_VBP also_RB able_JJ to_TO restrict_VB N_NP tropic_JJ MLV_NP ,_, and_CC it_PP will_MD be_VB interesting_JJ to_TO investigate_VB the_DT relationship_NN between_IN restrictions_NNS against_IN C-type_NP retrovirus_NN and_CC lentivirus_NN ._SENT The_DT large_JJ amount_NN of_IN retroviral_JJ sequence_NN in_IN mammalian_JJ genomes_NNS could_MD serve_VB as_IN a_DT pool_NN from_IN which_WDT protective_JJ sequence_NN can_MD be_VB selected_VBN by_IN pressure_NN from_IN pathogenic_JJ retrovirus_NN ._SENT Some_DT common_JJ aspects_NNS of_IN the_DT life_NN cycle_NN of_IN distantly_RB related_VBN retroviruses_NNS may_MD present_VB a_DT capsid_NN target_NN susceptible_JJ to_TO interference_NN from_IN gag-related_JJ molecules_NNS ,_, which_WDT depend_VBP on_IN their_PP$ gag-like_JJ nature_NN for_IN their_PP$ protective_JJ function_NN ._SENT The_DT further_JJR characterization_NN and_CC cloning_VBG of_IN these_DT factors_NNS will_MD provide_VB insight_NN into_IN early_JJ postentry_NN events_NNS in_IN the_DT retroviral_JJ life_NN cycle_NN and_CC reveal_VB opportunities_NNS for_IN therapeutic_JJ intervention_NN ._SENT Abbreviations_NNS :_: MLV_NP =_SYM murine_JJ leukemia_NN virus_NN simian_JJ immunodeficiency_NN virus_NN SIV_NP from_IN macaques_NNS enhanced_VBN green_JJ fluorescent_JJ protein_NN beta-galactosidase_NN fluorescence-activated_JJ cell_NN sorter_NN puromycin_NN resistance_NN G_NP =_SYM vesicular_JJ stomatitis_NN virus_NN envelope_NN protein_NN infectious_JJ units_NNS 